Publications » Lancet publishes paper on the Visby Medical point-of-care PCR technology

11/23/2020Publication

Lancet publishes paper on the Visby Medical point-of-care PCR technology

A study of the performance of the Visby Medical Sexual Health Test, a single-use, point-of-care PCR device.

Lancet publishes paper on the Visby Medical point-of-care PCR technology

Authors:  Sheldon R Morris, MD; Claire C Bristow, PhD; Michael R Wierzbicki, PhD; Mark Sarno, eJD; Lenore Asbel, MD; Audrey French, MD; Charlotte A Gaydos, DrPH; Lydie Hazan, MD; Leandro Mena, MD; Purnima Madhivanan, MD; Susan Philip, MD; Saara Schwartz, MD; Constance Brown, MD; David Styers, BS; Toni Waymer, BA; Jeffrey D Klausner, MD

Published: November 23, 2020

Summary:

Background

Timely detection and treatment are important for the control of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis. The objective of this study was to measure the performance of the Visby Medical Sexual Health Test, a single-use, point-of-care PCR device.

Methods

Women aged 14 years and older who presented consecutively to ten clinical sites across seven US states were enrolled for a cross-sectional, single-visit study. Patients who consented to participate, and who had not used any exclusionary products in the genital area in the previous 48 h, provided self-collected vaginal swabs for testing with the investigational device. Untrained operators received the specimens and ran the device using the guide provided. Specimens had to be run within 2 h of collection to be considered valid. For comparison, patient-infected status was derived by testing clinician-collected vaginal specimens with the Hologic Aptima Combo 2 Assay and Aptima Trichomonas vaginalis Assay, as well as the BD ProbeTec CT/GC Qx Amplified DNA Assay and BD ProbeTec Trichomonas vaginalis Qx Assay. If the results of those assays did not match, the BD MAX CT/GC/TV was used as a tiebreaker. The primary outcomes were the sensitivity and specificity of the investigational device for the detection of C trachomatis, N gonorrhoeae, and T vaginalis compared with patient-infected status.

Findings

Between Feb 25, 2019, and Jan 6, 2020, 1585 participants aged between 14 years and 80 years (mean 34·8 [SD 14·2]) were enrolled. 1555 participants had tests run with the investigational device, of whom 1532 (98·5%) had a valid result on either the first or repeat test. Among the patients with evaluable results (including a determinate patient-infected status), the device had a sensitivity of 97·6% (95% CI 93·2–99·2) and specificity of 98·3% (97·5–98·9) for C trachomatis (n=1457), sensitivity of 97·4% (86·5–99·5) and specificity of 99·4% (98·9–99·7) for N gonorrhoeae (n=1468), and sensitivity of 99·2% (95·5–99·9) and specificity of 96·9% (95·8–97·7) for T vaginalis (n=1449).

Interpretation

This innovative, rapid, easy-to-use, single-use, point-of-care device to detect C trachomatis, N gonorrhoeae, and T vaginalis infections showed excellent sensitivity and specificity, and could represent an important advance in the development of rapid diagnostics for sexually transmitted infections and other infectious diseases.

Funding

Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases.

 

See the full article here:

 

Read more articles & insights

08/19/2022Viewpoint

Visby Collaborates with Urgent Care Leaders in Scottsdale, AZ

Visby Medical will exhibit at the 14th Annual ConvUrgent Care Symposium. Since 2008, this conference has gathered healthcare leaders into a community around the increasing consumerization of medical care.

Read More
Visby Collaborates with Urgent Care Leaders in Scottsdale, AZ

08/16/2022Viewpoint

Why Should We Test for Trichomonas?

Trichomoniasis, commonly known as “trich,” is one of the most common sexually transmitted infections (STIs). It is caused by a one-celled parasite, Trichomonas vaginalis. Men and women are affected by this infection, but it occurs more often in women.

Read More
Why Should We Test for Trichomonas?

08/12/2022Viewpoint

Video Highlights from Visby Medical’s Breakfast Panel at 2022 IDSOG Annual Meeting

Watch video highlights from “The Neglected Epidemic: A Panel Discussion about the Value Rapid POC PCR brings to Reproductive Health” panel discussion at the 2022 IDSOG Annual Meeting.

Read More
Video Highlights from Visby Medical’s Breakfast Panel at 2022 IDSOG Annual Meeting

07/18/2022Viewpoint

Visby Medical Exhibits at 2022 IDSOG in Boston

For two great ways to learn about Visby rapid PCR, stop by table #6 or catch the breakfast panel discussion on Thursday, August 4 at 7am, all at Revere Hotel Boston Common in Boston, August 4-6.

Read More
Visby Medical Exhibits at 2022 IDSOG in Boston